{"id":4360,"date":"2025-10-24T14:24:09","date_gmt":"2025-10-24T11:24:09","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=4360"},"modified":"2025-10-24T14:25:34","modified_gmt":"2025-10-24T11:25:34","slug":"meme-kanserinde-kisisellestirilmis-tedavi-yaklasimiyla-10-yilda-254-milyar-tl-tasarruf-mumkun","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=4360","title":{"rendered":"Meme Kanserinde Ki\u015fiselle\u015ftirilmi\u015f Tedavi Yakla\u015f\u0131m\u0131yla 10 y\u0131lda 25,4 milyar TL Tasarruf M\u00fcmk\u00fcn"},"content":{"rendered":"\n<p><strong>Ekim Meme Kanseri Fark\u0131ndal\u0131k Ay\u0131 kapsam\u0131nda Roche \u0130la\u00e7 T\u00fcrkiye\u2019nin katk\u0131lar\u0131yla haz\u0131rlanan \u2018Erken Evre HER2+ Meme Kanserinde Ki\u015fiselle\u015ftirilmi\u015f Tedavi Yakla\u015f\u0131mlar\u0131n\u0131n Klinik, Ekonomik ve Toplumsal De\u011feri\u2019 \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131 a\u00e7\u0131kland\u0131. \u00c7al\u0131\u015fma, erken evre meme kanserinde tedavi yakla\u015f\u0131m\u0131n\u0131n kad\u0131nlar\u0131n ya\u015fam kalitesini, i\u015f g\u00fcc\u00fcne kat\u0131l\u0131m\u0131n\u0131 ve toplumsal \u00fcretkenli\u011fi destekleyerek sa\u011fl\u0131k sistemine uzun vadeli de\u011fer yaratt\u0131\u011f\u0131n\u0131 ortaya koyuyor.<\/strong><\/p>\n\n\n\n<p>Meme kanseri, d\u00fcnyada oldu\u011fu gibi T\u00fcrkiye\u2019de de kad\u0131nlarda en s\u0131k g\u00f6r\u00fclen kanser t\u00fcr\u00fc. Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 verilerine g\u00f6re T\u00fcrkiye\u2019de her 100 bin kad\u0131ndan 43\u2019\u00fc meme kanseri tan\u0131s\u0131 al\u0131yor. Erken tan\u0131 ve do\u011fru tedavi sayesinde art\u0131k \u00e7ok daha fazla hasta sa\u011fl\u0131\u011f\u0131na kavu\u015furken bu ba\u015far\u0131 yaln\u0131zca klinik d\u00fczeyde de\u011fil, hastal\u0131\u011f\u0131n toplumsal ve ekonomik y\u00fck\u00fc a\u00e7\u0131s\u0131ndan da belirgin bir fark yarat\u0131yor.<strong> <\/strong>Kad\u0131nlar\u0131n i\u015f ve sosyal ya\u015famlar\u0131na daha h\u0131zl\u0131 d\u00f6nebilmesi, ekonomik ve sosyal hayatta yer almaya devam edebilmeleri ve her \u015feyden \u00f6nce daha uzun ve daha sa\u011fl\u0131kl\u0131 bir ya\u015fam s\u00fcrebilmeleri, ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131mlar\u0131n\u0131n toplumsal etkisini a\u00e7\u0131k\u00e7a g\u00f6steriyor.<\/p>\n\n\n\n<p><strong>Ekim Meme Kanseri Fark\u0131ndal\u0131k Ay\u0131 kapsam\u0131nda<\/strong>, <strong>Roche \u0130la\u00e7 T\u00fcrkiye<\/strong>\u2019nin katk\u0131lar\u0131yla Ba\u015fkent \u00dcniversitesi Sa\u011fl\u0131k Bilimleri Fak\u00fcltesi \u00d6\u011fretim \u00dcyesi<strong>&nbsp;Prof. Dr. Simten Malhan<\/strong> ve Ankara \u015eehir Hastanesi T\u0131bbi Onkoloji Klini\u011fi E\u011fitim G\u00f6revlisi <strong>Prof. Dr. Mehmet Ali Nahit \u015eendur<\/strong> taraf\u0131ndan haz\u0131rlanan <strong>\u2018Erken Evre HER2+ Meme Kanserinde Ki\u015fiselle\u015ftirilmi\u015f Tedavi Yakla\u015f\u0131mlar\u0131n\u0131n Klinik, Ekonomik ve Toplumsal De\u011feri\u2019<\/strong> ara\u015ft\u0131rmas\u0131n\u0131n sonu\u00e7lar\u0131 payla\u015f\u0131ld\u0131.&nbsp;<\/p>\n\n\n\n<p>Ara\u015ft\u0131rma, erken evre meme kanserinde ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131mlar\u0131n\u0131n yaln\u0131zca hastalar i\u00e7in de\u011fil, sa\u011fl\u0131k sistemi ve toplum i\u00e7in de yaratt\u0131\u011f\u0131 de\u011feri bilimsel verilerle ortaya koyuyor. \u00c7al\u0131\u015fmada, 2019\u20132030 d\u00f6nemi i\u00e7in T\u00fcrkiye\u2019de geli\u015ftirilen HER2+ Erken Evre Meme Kanseri Etki Modeli sonu\u00e7lar\u0131 sunularak; klinik, ekonomik ve toplumsal faydalar\u0131 b\u00fct\u00fcnc\u00fcl bi\u00e7imde de\u011ferlendirildi.<\/p>\n\n\n\n<p><strong>Meme kanserinde geri kazan\u0131lan 102 binden fazla ya\u015fam y\u0131l\u0131<\/strong><\/p>\n\n\n\n<p>\u00c7al\u0131\u015fmaya g\u00f6re, ki\u015fiselle\u015ftirilmi\u015f tedavi stratejileri sayesinde 10 y\u0131l i\u00e7inde 3 bin 859 kad\u0131nda metastaz geli\u015fiminin \u00f6nlenebilece\u011fi \u00f6ng\u00f6r\u00fcl\u00fcyor. Bu sonu\u00e7, yaln\u0131zca ya\u015fam s\u00fcresinin uzamas\u0131 de\u011fil; kad\u0131nlar\u0131n daha sa\u011fl\u0131kl\u0131, aktif ve \u00fcretken y\u0131llar kazanmas\u0131 anlam\u0131na geliyor. \u00c7al\u0131\u015fma kapsam\u0131nda haz\u0131rlanan model, 102 bin 183 ya\u015fam y\u0131l\u0131, 79 bin 877 kaliteye ayarlanm\u0131\u015f ya\u015fam y\u0131l\u0131 ve 63 bin 294 \u00fcretken ya\u015fam y\u0131l\u0131 kazanc\u0131n\u0131 ortaya koyuyor.\u00b9 Bu tablo, erken tan\u0131 ve ki\u015fiselle\u015ftirilmi\u015f tedavilerin hem birey hem toplum d\u00fczeyinde yaratt\u0131\u011f\u0131 geri kazan\u0131lm\u0131\u015f ya\u015fam ve toplumsal katk\u0131 etkisini a\u00e7\u0131k\u00e7a g\u00f6steriyor.<\/p>\n\n\n\n<p><strong>10 y\u0131lda 25,4 milyar TL maliyet tasarrufu<\/strong><strong><\/strong><\/p>\n\n\n\n<p>\u00c7al\u0131\u015fman\u0131n ekonomik y\u00fck oda\u011f\u0131 kapsam\u0131nda, meme kanseriyle ili\u015fkili toplam maliyetin yakla\u015f\u0131k y\u00fczde 75\u2019i dolayl\u0131 maliyetlerden (i\u015f g\u00fcc\u00fc kayb\u0131, \u00fcretkenlik azalmas\u0131, bak\u0131m masraflar\u0131 vb.) olu\u015fuyor. \u00a0Bu durum, erken evrede do\u011fru tedaviye eri\u015fimin yaln\u0131zca klinik de\u011fil, ekonomik a\u00e7\u0131dan da stratejik bir \u00f6nem ta\u015f\u0131d\u0131\u011f\u0131n\u0131 g\u00f6steriyor. Ara\u015ft\u0131rmada, erken evrede uygulanan tedavilerin sa\u011fl\u0131k sistemi genelinde10 y\u0131ll\u0131k d\u00f6nemde<strong> 25,4 milyar TL <\/strong>d\u00fczeyinde do\u011frudan maliyet tasarrufu ve ula\u015f\u0131m ile bak\u0131m gibi t\u0131bbi olmayan kalemlerde yakla\u015f\u0131k <strong>7,1 milyar TL<\/strong> tutar\u0131nda dolayl\u0131 tasarruf sa\u011flad\u0131\u011f\u0131 belirtiliyor.<br><\/p>\n\n\n\n<p>Raporun makroekonomik bulgular\u0131 ise, erken evre tedavilerin yaln\u0131zca sa\u011fl\u0131k b\u00fct\u00e7esi \u00fczerindeki etkileriyle s\u0131n\u0131rl\u0131 kalmad\u0131\u011f\u0131n\u0131 g\u00f6steriyor.\u00b9 \u00c7al\u0131\u015fmada, erken evre tedavi g\u00f6ren bireylerin i\u015f g\u00fcc\u00fcne kazan\u0131m oranlar\u0131n\u0131n artt\u0131\u011f\u0131 ve \u00fcretkenlik kayb\u0131n\u0131n azald\u0131\u011f\u0131 g\u00f6r\u00fcl\u00fcyor. Bu sonu\u00e7 hem vergi gelirleri hem de sosyal g\u00fcvenlik primleri a\u00e7\u0131s\u0131ndan sa\u011fl\u0131k yat\u0131r\u0131mlar\u0131n\u0131n uzun vadeli s\u00fcrd\u00fcr\u00fclebilirli\u011fe katk\u0131 sundu\u011funu ortaya koyuyor.<\/p>\n\n\n\n<p><strong>Erken evre tedaviler, kad\u0131nlar\u0131n ekonomik ve sosyal ya\u015fama kat\u0131l\u0131m\u0131n\u0131 g\u00fc\u00e7lendirirken sa\u011fl\u0131k sistemlerinin s\u00fcrd\u00fcr\u00fclebilirli\u011fine katk\u0131 sa\u011fl\u0131yor<\/strong><\/p>\n\n\n\n<p>Konuyla ilgili de\u011ferlendirmede bulunan <strong>Ba\u015fkent \u00dcniversitesi Sa\u011fl\u0131k Bilimleri Fak\u00fcltesi \u00d6\u011fretim \u00dcyesi<\/strong>&nbsp;<strong>Prof. Dr. Simten Malhan<\/strong>, \u201c\u00c7al\u0131\u015fman\u0131n bulgular\u0131, erken evre meme kanserinde ki\u015fiselle\u015ftirilmi\u015f tedavilere yap\u0131lan yat\u0131r\u0131mlar\u0131n uzun vadede sa\u011fl\u0131k sisteminin gelece\u011fine yap\u0131lan stratejik bir yat\u0131r\u0131m oldu\u011funu g\u00f6steriyor. Bu tedaviler, ilerleyen d\u00f6nemde ortaya \u00e7\u0131kabilecek metastatik hastal\u0131k y\u00fck\u00fcn\u00fc azaltarak hem do\u011frudan sa\u011fl\u0131k harcamalar\u0131n\u0131 d\u00fc\u015f\u00fcr\u00fcyor hem de dolayl\u0131 maliyetlerde belirgin iyile\u015fme sa\u011fl\u0131yor. Kad\u0131nlar\u0131n i\u015f ve sosyal ya\u015famlar\u0131na daha h\u0131zl\u0131 d\u00f6nebilmesi, ya\u015famlar\u0131ndaki aktif rollerini s\u00fcrd\u00fcrebilmeleri ve bak\u0131m ihtiyac\u0131n\u0131n azalmas\u0131, bu yakla\u015f\u0131m\u0131n toplumsal de\u011ferini somut bi\u00e7imde ortaya koyuyor. Sa\u011fl\u0131k ekonomisi perspektifinden bak\u0131ld\u0131\u011f\u0131nda, erken evre tedaviler sa\u011fl\u0131k sistemlerinin s\u00fcrd\u00fcr\u00fclebilirli\u011fini g\u00fc\u00e7lendiren ve uzun vadeli refah art\u0131\u015f\u0131na katk\u0131 sa\u011flayan en \u00f6nemli unsurlar aras\u0131nda yer al\u0131yor. Bu \u00e7al\u0131\u015fman\u0131n ortaya koydu\u011fu 25 milyar TL\u2019lik ekonomik katk\u0131 ile uzun d\u00f6nemde sa\u011fl\u0131k ekosisteminin desteklenmesine y\u00f6nelik Ar-Ge, inovasyon \u00e7al\u0131\u015fmalar\u0131 ve klinik ara\u015ft\u0131rmalar ile farkl\u0131 tedavi alanlar\u0131nda hastalar\u0131n ya\u015famlar\u0131n\u0131 d\u00f6n\u00fc\u015ft\u00fcr\u00fcc\u00fc \u00e7ok de\u011ferli katk\u0131lar sa\u011flanmaya devam edilebilir\u201d dedi.<\/p>\n\n\n\n<p><strong>Ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131m\u0131yla hastalar daha uzun ve kaliteli bir ya\u015fam s\u00fcrebiliyor<\/strong><\/p>\n\n\n\n<p>Ara\u015ft\u0131rman\u0131n klinik boyutunu de\u011ferlendiren <strong>Ankara \u015eehir Hastanesi T\u0131bbi Onkoloji Klini\u011fi E\u011fitim G\u00f6revlisi Prof. Dr. Mehmet Ali Nahit \u015eendur<\/strong> ise erken tan\u0131 ve ki\u015fiselle\u015ftirilmi\u015f tedavilerin hastal\u0131k y\u00f6netiminde yaratt\u0131\u011f\u0131 fark\u0131n alt\u0131n\u0131 \u00e7izdi: \u201cErken tan\u0131, meme kanserinde tedavi ba\u015far\u0131s\u0131n\u0131n en kritik ad\u0131m\u0131. Ancak as\u0131l fark, her hastan\u0131n t\u0131bbi ve ki\u015fisel ihtiya\u00e7lar\u0131na g\u00f6re planlanan ki\u015fiselle\u015ftirilmi\u015f tedavi yakla\u015f\u0131mlar\u0131yla ortaya \u00e7\u0131k\u0131yor. Bu sayede hastal\u0131\u011f\u0131n metastatik evreye ilerlemesi \u00f6nlenebiliyor,&nbsp; kad\u0131nlar hem daha uzun hem de daha kaliteli bir ya\u015fam s\u00fcr\u00fcyor. Erken evre tedaviler, yaln\u0131zca klinik sonu\u00e7lar\u0131 iyile\u015ftirmekle kalm\u0131yor; ayn\u0131 zamanda hastalar\u0131n g\u00fcnl\u00fck ya\u015famlar\u0131, sosyal rolleri ve \u00fcretkenliklerini s\u00fcrd\u00fcrebilmelerini de m\u00fcmk\u00fcn k\u0131l\u0131yor. Bu yakla\u015f\u0131m, bireyin ya\u015fam kalitesini art\u0131r\u0131rken toplumun genel refah\u0131n\u0131 da g\u00fc\u00e7lendiriyor. Erken tan\u0131 ve do\u011fru tedaviye eri\u015fim, bug\u00fcn oldu\u011fu kadar gelecekte de hem birey hem toplum sa\u011fl\u0131\u011f\u0131 a\u00e7\u0131s\u0131ndan en g\u00fc\u00e7l\u00fc unsurlardan biri olacak.\u201d<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<p><a href=\"#_ftnref1\" id=\"_ftn1\"><\/a>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ekim Meme Kanseri Fark\u0131ndal\u0131k Ay\u0131 kapsam\u0131nda Roche \u0130la\u00e7 T\u00fcrkiye\u2019nin katk\u0131lar\u0131yla haz\u0131rlanan \u2018Erken Evre HER2+ Meme Kanserinde Ki\u015fiselle\u015ftirilmi\u015f Tedavi Yakla\u015f\u0131mlar\u0131n\u0131n Klinik, Ekonomik ve Toplumsal De\u011feri\u2019 \u00e7al\u0131\u015fmas\u0131n\u0131n sonu\u00e7lar\u0131 a\u00e7\u0131kland\u0131. \u00c7al\u0131\u015fma, erken evre meme kanserinde tedavi yakla\u015f\u0131m\u0131n\u0131n kad\u0131nlar\u0131n ya\u015fam kalitesini, i\u015f g\u00fcc\u00fcne kat\u0131l\u0131m\u0131n\u0131 ve toplumsal \u00fcretkenli\u011fi destekleyerek sa\u011fl\u0131k sistemine uzun vadeli de\u011fer yaratt\u0131\u011f\u0131n\u0131 ortaya koyuyor.<\/p>\n","protected":false},"author":1,"featured_media":4361,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,3],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4360"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4360"}],"version-history":[{"count":2,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4360\/revisions"}],"predecessor-version":[{"id":4363,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/4360\/revisions\/4363"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/4361"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}